Gpcr Therapeutics company information, Employees & Contact Information

Designing allosteric modulators to change GPCR G protein subtype selectivity Nature

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. Business Wire

Is Structure Therapeutics Inc. (GPCR) the Best Weight Loss Stock to Buy Now According to Hedge Funds? Yahoo Finance

GPCR Therapeutics Announces Out-Licensing Agreement with Bridge Biotherapeutics in Idiopathic Pulmonary Fibrosis GlobeNewswire

GPCR therapies: Eight promising biotechs hacking the cell signaling pathway Labiotech.eu

Monash researchers founding scientists of new GPCR biotechnology company launched with AUD$140 million in financing Monash University

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc. BioSpace

Agonist activation to open the Gα subunit of the GPCR–G protein precoupled complex defines functional agonist activation of TAS2R5 PNAS

The next era for GPCR-focused biopharma Nature

GPCR-targeting drugs: A renewed focus on a ubiquitous group of proteins BioPharma Dive

GPCR Therapeutics Expands Pipeline into Fibrosis with a Combination Approach Targeting LPA1 Yahoo Finance

UK Biotech Closes €50M Series A for GPCR Drug Discovery Labiotech.eu

Is there a renaissance in GPCR drug development? Nature

Why Is Structure Therapeutics Inc. (GPCR) Among the Best Up and Coming Stocks to Buy According to Analysts? Yahoo Finance

ESTY as an optimized cell-based assay for initial steps in GPCR deorphanization Nature

Specific pharmacological and Gi/o protein responses of some native GPCRs in neurons | Nature Communications Nature

Dissecting the genetic landscape of GPCR signaling through phenotypic profiling in C. elegans Nature

AI meets physics in computational structure-based drug discovery for GPCRs Nature

Septerna: making another run on GPCRs Nature

Thermodynamic architecture and conformational plasticity of GPCRs Nature

Functionally distinct and selectively phosphorylated GPCR subpopulations co-exist in a single cell Nature

GPCR drugmaker Septerna amasses $288M in IPO BioPharma Dive

Multidimensional Tracking of GPCR Signaling via Peroxidase-Catalyzed Proximity Labeling ScienceDirect.com

Development of an antibody fragment that stabilizes GPCR/G-protein complexes Nature

Septerna files for IPO on strength of preclinical data, vision for expanding GPCR landscape Fierce Biotech

Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with pioneer as co-founder Fierce Biotech

Tectonic Therapeutic banks $80M to shift GPCR drug discovery toward biologics Fierce Biotech

An Actin Network Dispatches Ciliary GPCRs into Extracellular Vesicles to Modulate Signaling ScienceDirect.com

Superluminal draws RA Capital, Nvidia as investors in GPCR drug hunt BioPharma Dive

ER/K linked GPCR-G protein fusions systematically modulate second messenger response in cells Nature

Systematic protein–protein interaction mapping for clinically relevant human GPCRs | Molecular Systems Biology EMBO Press

Septerna to Present Preclinical Data from GPCR Drug Discovery Engine at ENDO 2024 Business Wire

Crystal structure of a common GPCR-binding interface for G protein and arrestin Nature

Status of GPCR Modeling and Docking as Reflected by Community-wide GPCR Dock 2010 Assessment ScienceDirect.com

GPCR passes Technology Evaluation process for listing on KOSDAQ 바이오스펙테이터

DIGMBIO’s DM3100 Targets ‘Taste Receptor’ in Alzheimer’s 디멘시아뉴스